-
1.发明申请公开(公告)号：US20180289640A1
公开(公告)日：2018-10-11
申请号：US16010205
申请日：2018-06-15
CPC分类号： A61K31/137 , A61K9/0014 , A61K9/06 , A61K9/7061 , A61K47/14 , A61K47/20 , A61K47/32 , A61K47/38
摘要： Topical sphingosine-1-phosphate receptor agonist active agent formulations are provided. Aspects of the transdermal formulations include an amount of a sphingosine-1-phosphate receptor agonist active agent in combination with a topical delivery vehicle, e.g., a topical patch that includes an adhesive layer and a backing layer. Also provided are methods of topically delivering a therapeutically effective amount of a sphingosine-1-phosphate receptor agonist active agent to a subject, e.g., to treat a subject for a disease condition, such as an immune system disorder like multiple sclerosis, a hyperproliferative dermatological disorder, e.g., psoriasis, acne, etc. Packaged topical formulations, kits including such formulations, and methods of making such formulations are also provided.
-
公开(公告)号：US09827207B2
公开(公告)日：2017-11-28
申请号：US14933598
申请日：2015-11-05
发明人： Richard D. Hamlin , Amit Jain , Jianye Wen
IPC分类号： A61K31/135 , A61K47/32 , A61K9/70
CPC分类号： A61K9/7061 , A61K9/7084 , A61K31/135
摘要： Propynylaminoindan (e.g., Rasagiline) transdermal compositions are provided. Aspects of the transdermal compositions include a matrix which includes the propynylaminoindan, a pressure sensitive adhesive that includes an acrylate copolymer and a cationic acrylic copolymer. Also provided are methods of using the transdermal compositions and kits containing the transdermal compositions.
-
公开(公告)号：US09763880B2
公开(公告)日：2017-09-19
申请号：US15066087
申请日：2016-03-10
发明人： Kiichiro Nabeta
IPC分类号： A61K31/335 , A61K9/10 , A61K31/337 , A61K47/10 , A61K47/12 , A61K47/14 , A61K47/26 , A61K47/44
摘要： Non-aqueous, ethanol-free taxane formulations are provided. Formulations of embodiments of the invention include a taxane, an oil, a non-ionic surfactant, a non-aqueous solvent, and an organic acid component, wherein the organic acid component is soluble in the non-aqueous solvent and the amount by weight of non-ionic surfactant is equal to or greater than the amount by weight of non-aqueous solvent. Also provided are methods of using the formulations, as well as kits that include the formulations. Non-aqueous, ethanol-free docetaxel formulations are provided. Formulations of embodiments of the invention include docetaxel, an oil, a non-ionic surfactant, a non-aqueous solvent, and an organic acid which is soluble in the non-aqueous solvent and is substantially free of any conjugate base. Also provided are methods of using the formulations, as well as kits that include the formulations.
-
公开(公告)号：US09427435B2
公开(公告)日：2016-08-30
申请号：US14492509
申请日：2014-09-22
发明人： Kiichiro Nabeta , Toru Hibi
IPC分类号： A61K31/4468 , A61P29/00 , A61K9/00 , A61K9/107 , A61K47/10 , A61K47/24 , A61K47/12 , A61K47/44
CPC分类号： A61K31/4468 , A61K9/0019 , A61K9/107 , A61K47/10 , A61K47/12 , A61K47/24 , A61K47/44
摘要： Methods and compositions of treating a subject for cancer pain are provided. In the subject methods, a subject is treated for cancer pain by administering to the subject an effective amount of a narcotic emulsion, e.g., fentanyl elmulsion, formulation. In certain embodiments, the emulsion formulations include a narcotic active agent, oil, water and a surfactant. Also provided are methods of making the subject emulsion formulations as well as kits that include the emulsion formulations.
摘要翻译： 提供了治疗受试者癌症疼痛的方法和组合物。 在本发明的方法中，通过向受试者施用有效量的麻醉乳剂，例如芬太尼乳液，制剂，治疗受试者的癌症疼痛。 在某些实施方案中，乳液制剂包括麻醉活性剂，油，水和表面活性剂。 还提供了制备主题乳液制剂的方法以及包括乳液制剂的试剂盒。
-
公开(公告)号：US09308195B2
公开(公告)日：2016-04-12
申请号：US14564384
申请日：2014-12-09
发明人： Kiichiro Nabeta
摘要： Non-aqueous, ethanol-free taxane formulations are provided. Formulations of embodiments of the invention include a taxane, an oil, a non-ionic surfactant, a non-aqueous solvent, and an organic acid component, wherein the organic acid component is soluble in the non-aqueous solvent and the amount by weight of non-ionic surfactant is equal to or greater than the amount by weight of non-aqueous solvent. Also provided are methods of using the formulations, as well as kits that include the formulations. Non-aqueous, ethanol-free docetaxel formulations are provided. Formulations of embodiments of the invention include docetaxel, an oil, a non-ionic surfactant, a non-aqueous solvent, and an organic acid which is soluble in the non-aqueous solvent and is substantially free of any conjugate base. Also provided are methods of using the formulations, as well as kits that include the formulations.
摘要翻译： 提供非水，无乙醇的紫杉烷制剂。 本发明的实施方案的制剂包括紫杉烷，油，非离子表面活性剂，非水溶剂和有机酸组分，其中有机酸组分可溶于非水溶剂中， 非离子表面活性剂等于或大于非水溶剂的重量。 还提供了使用制剂的方法，以及包括制剂的试剂盒。 提供非水，无乙醇的多西紫杉醇制剂。 本发明实施方案的制剂包括多西他赛，油，非离子表面活性剂，非水溶剂和可溶于非水溶剂中并基本上不含任何共轭碱的有机酸。 还提供了使用制剂的方法，以及包括制剂的试剂盒。
-
公开(公告)号：US20160051489A1
公开(公告)日：2016-02-25
申请号：US14933598
申请日：2015-11-05
发明人： Richard D. Hamlin , Amit Jain , Jianye Wen
IPC分类号： A61K9/70 , A61K31/135
CPC分类号： A61K9/7061 , A61K9/7084 , A61K31/135
摘要： Propynylaminoindan (e.g., Rasagiline) transdermal compositions are provided. Aspects of the transdermal compositions include a matrix which includes the propynylaminoindan, a pressure sensitive adhesive that includes an acrylate copolymer and a cationic acrylic copolymer. Also provided are methods of using the transdermal compositions and kits containing the transdermal compositions.
摘要翻译： 提供丙炔基氨基茚满（如雷沙吉兰）透皮组合物。 透皮组合物的方面包括包含丙炔基氨基茚满的基质，包含丙烯酸酯共聚物和阳离子丙烯酸共聚物的压敏粘合剂。 还提供了使用含有透皮组合物的透皮组合物和试剂盒的方法。
-
公开(公告)号：US20150141461A1
公开(公告)日：2015-05-21
申请号：US14492509
申请日：2014-09-22
发明人： Kiichiro Nabeta , Toru Hibi
CPC分类号： A61K31/4468 , A61K9/0019 , A61K9/107 , A61K47/10 , A61K47/12 , A61K47/24 , A61K47/44
摘要： Methods and compositions of treating a subject for cancer pain are provided. In the subject methods, a subject is treated for cancer pain by administering to the subject an effective amount of a narcotic emulsion, e.g., fentanyl elmulsion, formulation. In certain embodiments, the emulsion formulations include a narcotic active agent, oil, water and a surfactant. Also provided are methods of making the subject emulsion formulations as well as kits that include the emulsion formulations.
摘要翻译： 提供了治疗受试者癌症疼痛的方法和组合物。 在本发明的方法中，通过向受试者施用有效量的麻醉乳剂，例如芬太尼乳液，制剂，治疗受试者的癌症疼痛。 在某些实施方案中，乳液制剂包括麻醉活性剂，油，水和表面活性剂。 还提供了制备主题乳液制剂的方法以及包括乳液制剂的试剂盒。
-
8.发明申请Topical Sphingosine-1-Phosphate Receptor Agonist Formulations and Methods of Using the Same 有权局部鞘氨醇-1-磷酸酯受体激动剂制剂及其使用方法公开(公告)号：US20150104497A1
公开(公告)日：2015-04-16
申请号：US14473462
申请日：2014-08-29
IPC分类号： A61K31/137 , A61K9/70
CPC分类号： A61K31/137 , A61K9/0014 , A61K9/06 , A61K9/7061 , A61K47/14 , A61K47/20 , A61K47/32 , A61K47/38
摘要： Topical sphingosine-1-phosphate receptor agonist active agent formulations are provided. Aspects of the transdermal formulations include an amount of a sphingosine-1-phosphate receptor agonist active agent in combination with a topical delivery vehicle, e.g., a topical patch that includes an adhesive layer and a backing layer. Also provided are methods of topically delivering a therapeutically effective amount of a sphingosine-1-phosphate receptor agonist active agent to a subject, e.g., to treat a subject for a disease condition, such as an immune system disorder like multiple sclerosis, a hyperproliferative dermatological disorder, e.g., psoriasis, acne, etc. Packaged topical formulations, kits including such formulations, and methods of making such formulations are also provided.
摘要翻译： 提供局部鞘氨醇-1-磷酸受体激动剂活性剂制剂。 透皮制剂的方面包括一定量的鞘氨醇-1-磷酸受体激动剂活性剂与局部递送载体组合，例如包括粘合剂层和背衬层的局部贴剂。 还提供了向受试者局部递送治疗有效量的鞘氨醇-1-磷酸受体激动剂活性剂的方法，例如用于治疗受试者的疾病状况，例如多发性硬化症等免疫系统疾病，过度增生性皮肤病学 障碍，例如牛皮癣，痤疮等。还提供了包装的局部制剂，包括这些制剂的试剂盒以及制备这些制剂的方法。
-
9.发明申请Methods and Compositions for Treating Withdrawal Syndromes Using Non-Sedative Dexmedetomidine Transdermal Compositions 审中-公开使用非镇静性美替米丹透皮组合物治疗戒断综合征的方法和组合公开(公告)号：US20150098983A1
公开(公告)日：2015-04-09
申请号：US14505943
申请日：2014-10-03
发明人： Adchara Pongpeerapat , Amit Jain , Bret Berner , Jianye Wen , Jutaro Shudo
IPC分类号： A61K31/4174 , A61K9/70
CPC分类号： A61K31/4174 , A61K9/7053 , A61K9/7061 , A61K47/12 , A61K47/32
摘要： Aspects of the invention include methods of treating withdrawal syndrome by applying a transdermal delivery device containing a dexmedetomidine composition formulated to deliver a non-sedative amount of dexmedetomidine to a subject diagnosed as having withdrawal syndrome. In practicing methods according to certain embodiments, a transdermal delivery device having a dexmedetomidine composition is applied to a subject and is maintained in contact with the subject in a manner sufficient to deliver a non-sedative amount of dexmedetomidine to treat withdrawal syndrome in the subject. Also provided are transdermal delivery devices configured to deliver a non-sedative amount of dexmedetomidine sufficient for practicing the subject methods, as well as kits containing the transdermal delivery devices.
摘要翻译： 本发明的方面包括通过应用含有右美托咪定组合物的透皮递送装置来治疗戒断综合征的方法，以将非镇静剂量的右美托咪定输送到被诊断为具有戒断综合征的受试者。 在根据某些实施方案的实践方法中，将具有右美托咪定组合物的透皮递送装置施用于受试者，并以足以递送非镇静剂量的右美托咪定以治疗受试者的戒断综合征的方式与受试者保持接触。 还提供了经皮递送装置，其经配置以递送非镇静剂量的足以实施本发明方法的右美托咪定，以及含有透皮递送装置的试剂盒。
-
公开(公告)号：US20150094361A1
公开(公告)日：2015-04-02
申请号：US14564384
申请日：2014-12-09
发明人： Kiichiro Nabeta
摘要： Non-aqueous, ethanol-free taxane formulations are provided. Formulations of embodiments of the invention include a taxane, an oil, a non-ionic surfactant, a non-aqueous solvent, and an organic acid component, wherein the organic acid component is soluble in the non-aqueous solvent and the amount by weight of non-ionic surfactant is equal to or greater than the amount by weight of non-aqueous solvent. Also provided are methods of using the formulations, as well as kits that include the formulations. Non-aqueous, ethanol-free docetaxel formulations are provided. Formulations of embodiments of the invention include docetaxel, an oil, a non-ionic surfactant, a non-aqueous solvent, and an organic acid which is soluble in the non-aqueous solvent and is substantially free of any conjugate base. Also provided are methods of using the formulations, as well as kits that include the formulations.
摘要翻译： 提供非水，无乙醇的紫杉烷制剂。 本发明的实施方案的制剂包括紫杉烷，油，非离子表面活性剂，非水溶剂和有机酸组分，其中有机酸组分可溶于非水溶剂中， 非离子表面活性剂等于或大于非水溶剂的重量。 还提供了使用制剂的方法，以及包括制剂的试剂盒。 提供非水，无乙醇的多西紫杉醇制剂。 本发明实施方案的制剂包括多西他赛，油，非离子表面活性剂，非水溶剂和可溶于非水溶剂中并基本上不含任何共轭碱的有机酸。 还提供了使用制剂的方法，以及包括制剂的试剂盒。
-
-
-
-
-
-
-
-
-
搜索结果
66 条记录 (耗时 0.021 秒)
